BAM
KRTX

Belpointe Asset Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Belpointe Asset Management’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-57
Closed -$10.4K – 3601
2023
Q1 		$10.4K Buy
57
+34
+148% +$6.5K ﹤0.01% 2701
2022
Q4 		$4.52K Buy
+23
New +$4.93K ﹤0.01% 2974

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Belpointe Asset Management's KRTX Position: Q2 2023 in Review

Belpointe Asset Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q2 2023, closing a stake of 57 shares — an estimated $10.4K sold.

Belpointe Asset Management first reported a position in KRTX in Q4 2022 and held it in 2 quarters. The position peaked at $10.4K in Q1 2023. 289 funds tracked by Wall St. Rank hold KRTX as of Q2 2023.

  • Belpointe Asset Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 57 Karuna Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $10.4K.
  • Belpointe Asset Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Karuna Therapeutics, Inc. Common Stock position peaked at $10.4K in Q1 2023.
  • 289 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.